|
|
 |
|
Viewing report
|
|
|
|
The Eastern European Cancer Market Outlook to 2010
Business Insights, Dec 2005
The Eastern European Cancer Market Outlook to 2010 is a new management report which provides an in-depth analysis of growth brands, product sales forecasts, epidemiology and future market leaders over the period 2005-2010 in twelve major Eastern European cancer markets, including Hungary, Poland, the Czech Republic, Russian Federation, Slovenia, Slovakia and the Ukraine.
With a sales increase of over $0.5bn in the past five years, the Eastern European cancer market represents a strong opportunity for pharmaceutical marketers offering high levels of sales growth and market potential for a diversity of cancer products. The complexion of the Eastern European market is changing however and there currently exists a vibrant market for sales of innovative therapies, which have the potential for high rates of market penetration.
Tap into the growing market for innovative cancer therapies in Eastern Europe by using this latest report to identify the cancer market trends in developed and emerging
Eastern European countries, assess the dominant therapies driving market growth and develop potential growth and diversification strategies in this region over the period 2005-2010.
Geographic coverage...
- Belarus
- Bulgaria
- Czech Rep
- Estonia
- Hungary
- Latvia
- Lithuania
- Poland
- Russian Federation
- Slovakia
- Slovenia
- Ukraine
Nine major cancers...
- Prostate
- Lung
- Lymphoma
- Leukemia
- Colorectal
- Pancreatic
- Breast
- Ovarian
- Uterine
'Must have' statistics and analysis in this report
This report provides:
- Forecasts and analysis using gold standard IMS sales data of the major products in the Eastern European cancer market over the period 2005-2010 for the nine major cancers.
- Overview of healthcare programs and pharmaceutical spending across the twelve Eastern European cancer markets, as well as an examination of trends and future prospects.
- Company analysis and market share of the top eight players in the Eastern European cancer market, including Roche, Novartis, and AstraZeneca.
- Epidemiological analysis and forecasts for the nine major cancers across the twelve markets, including Poland, Hungary, the Czech Republic and the Russian Federation.
- Detailed analysis across four classes of cancer products, and late-stage pipelines in these classes.
Your questions answered
- What will be the major growth indications in the Eastern European cancer market over the period 2005-2010?
- How have recent major launches from Roche, Novartis, and Sanofi-Aventis performed across Eastern Europe?
- Which companies will become the key players in the Eastern European cancer market over the period 2005-2010?
- Which products will be impacted by generic competitors over the period 2005-2010?
- Which markets in the Eastern European region are the major growth drivers for cancer sales over the period 2005-2010?
- Which of the major cancers are forecast to have the highest incidence levels across Eastern European markets over the period 2005-2010?
- What will the competitive landscape in the major cancers (prostate, breast, lung, colorectal, ovarian, leukaemia, pancreatic, lymphoma, uterine) look like in Eastern Europe in 2010?
Actionable strategies to drive your profits forward
- Save valuable time and research budget with this report's epidemiological analysis and forecasts across the twelve Eastern European cancer markets, examination of the four major classes of cancer products using IMS data, and breakdown of the 8 largest cancer franchises active in the Eastern European region.
- Quickly understand how marketers are confronting competitive changes across Eastern European cancer markets and evaluate how recent events are affecting the performance of major products.
- Benchmark the successful oncology strategies of leading players including Novartis, Roche and AstraZeneca by analyzing up-to-date competitive intelligence across the twelve Eastern European markets.
- Optimize your strategic positioning across Eastern European cancer markets forecast to have the greatest increase in incidence and develop strategies to meet the needs of these growing markets.
- Identify future market leaders by using head-to-head comparisons of newly launched cancer products across Eastern European markets to understand which companies will have a presence among key indications over the next six years
Customers who bought this item also bought
The Cancer Market Outlook to 2012
The Cancer Market Outlook to 2010
The Cancer Market Outlook to 2011
Commercial Insight: Antihormonal Cancer Therapies
The Eastern European Cardiovascular Market Outlook to 2010
The Asian Cancer Market Outlook to 2010
Drug Delivery in Cancer - Technologies, Markets and Companies
Cancer Therapeutics Markets
Biomarker Technology Platforms for Cancer Diagnoses and Therapies
The Latin American Cancer Market Outlook to 2010
Cancer Therapies - Global Strategic Business Report
Cancer Therapeutics - Market Insight and R&D Pipeline Analysis
|
|
|
|
